Radhika Tripuraneni - Mar 10, 2025 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Medical Officer
Signature
/s/ Jennifer Tousignant, Attorney-in-fact
Stock symbol
VRDN
Transactions as of
Mar 10, 2025
Transactions value $
$0
Form type
4
Date filed
3/12/2025, 04:36 PM
Previous filing
Feb 3, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Award $0 +311K $0.00 311K Mar 10, 2025 Common Stock 311K $15.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 25% on March 10, 2026 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date.